Lumleian > Capabilities > Academia and Non-Profits

Academia and Non-Profits

Academia and non-profits make significant contributions to life science innovation. Recent studies show that they were the primary source for approximately 24% of all new drug approvals over the past decade and have contributed research to approximately 80% of all new drug approvals.1

Lumleian supports clients in technology transfer, research administration, foundations, and other non-profit R&D sponsors. We are awed by the groundbreaking work they achieve. We strive to advance this innovation by providing precise, cost-effective decision support and facilitating successful partnerships with biopharmaceutical companies and life science investors.

Lumleian's Capabilities

To support offices of technology transfer, deans of research in academia, research institutes, disease foundations, and select government agencies in their advancement of translational science, Lumleian has four core capabilities:

  • Disease State Primers: These comprehensive reports, updated quarterly, provide the requisite information to position and value assets. Our primers centralize all available secondary data, detailing the disease and care paradigms, clinical development pipeline, and commercial landscape for a disease. Download a sample primer.

  • Clinical Strategy and Asset Valuation: We identify the most attractive market positioning for a given asset based on its profile and the competitive landscape. To value the asset, we forecast future revenue streams based on relevant benchmarks and surveys with practitioners.
  • Transaction Support: We support academic and research institution clients during both out-licensing and spinout transactions by:

    • Engaging potential biopharmaceutical companies and life science investors.

    • Articulating a compelling investment thesis and business case for their assets.

    • Valuing alternative bids and deal terms, and participating in negotiations.

  • Early Stage Portfolio Optimization: Using advanced analytics, we help identify and prioritize R&D programs that are most likely to realize clinical success. We identify assets with the greatest potential for out-licensing to biopharmaceutical companies or spinout to life science investors.

1 Kneller, R. The importance of new companies for drug discovery: origins of a decade of new dugs. Nature Reviews Drug Discovery. 9, 867-882 (2010).
Stevens A. J. et al. The role of public-sector research in the discovery of drugs and vaccines. New England Journal of Medicine. 364, 535-41 (2011).
Zycher B. et al. Private sector contributions to pharmaceutical science: thirty-five summary case histories. American Journal of Therapeutics. 17(1), 101-20 (2010).